Long-acting albumin-binding GHRH receptor agonism · Peptide
Evidence gap: Human SC PK exists for the DAC molecule; absolute SC bioavailability and oral or IM therapeutic PK are not established here.
Open in the interactive library →Compare with other compounds →
Healthy-adult SC trials found a 5.8–8.1-day half-life and prolonged GH and IGF-1 elevation. These are DAC-containing molecule findings.
Context: October 15 2026 article audit; primary evidence and author claims distinguished.
Limitations: No established general treatment protocol; retain the population, molecule and route limitations.
Open this exact record in the library →Suggest a correctionHealthy men aged 20–40 received 60 or 90 mcg/kg; overnight sampling one week afterward showed 7.5-fold higher trough GH with unchanged pulse frequency and magnitude. This does not establish no-DAC superiority.
Context: October 15 2026 article audit; primary evidence and author claims distinguished.
Limitations: No established general treatment protocol; retain the population, molecule and route limitations.
Open this exact record in the library →Suggest a correctionAdministration reported for this specific study or labeled indication.
Context: Healthy adults
Human study regimen: Amount: 30, 60, 125 or 250 µg/kg; Route: Subcutaneous; Frequency: Single administration; Duration: 28-day study; Species: Human; Population: Healthy adults
Limitations: The trial measured GH and IGF-I and studied the long-acting DAC construct.
Open this exact record in the library →Suggest a correctionThese compounds share an Atlas pathway label. That is a navigation connection, not evidence of equivalent effects or suitability together.
Browse this pathway in the library →Educational research summary. Study amounts are research context, not a dose recommendation. Not medical advice.